(CGEM) Cullinan Oncology - Ratings and Ratios
Bispecific Antibody, Leukemia Drug, Oncology Pipeline
CGEM EPS (Earnings per Share)
CGEM Revenue
Description: CGEM Cullinan Oncology
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The companys pipeline includes several promising candidates, such as zipalertinib, a small molecule in Phase 3 trial for non-small cell lung cancer, and CLN-978, a T cell engager for treating systemic lupus erythematosus and rheumatoid arthritis.
From a clinical perspective, the progress of zipalertinib in Phase 3 trials is significant, as it indicates a potential breakthrough in treating non-small cell lung cancer. Additionally, CLN-978s potential in treating autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis could provide a new therapeutic option for patients. Key Performance Indicators (KPIs) to watch include the trial completion rates, patient response rates, and potential FDA approval timelines.
From a financial perspective, Cullinan Therapeutics has a market capitalization of $462.68M USD, with a forward P/E ratio of 6.30, indicating a relatively low valuation compared to its projected earnings. The companys return on equity (RoE) is -29.47, suggesting significant investment in research and development. KPIs to monitor include the companys cash burn rate, R&D expenses as a percentage of revenue, and potential milestone payments from partnerships.
The companys collaborations with Adimab, LLC and Taiho Pharmaceutical Co., Ltd are also noteworthy, as they provide access to new technologies and potential co-development opportunities. Key metrics to track include the progress of these collaborations, potential milestone payments, and the impact on the companys cash reserves.
Overall, Cullinan Therapeutics promising pipeline, collaborations, and relatively low valuation make it an interesting opportunity for investors. However, the high-risk nature of biopharmaceutical investments and the companys negative RoE require careful consideration of the potential risks and rewards.
CGEM Stock Overview
| Market Cap in USD | 456m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-01-08 |
CGEM Stock Ratings
| Growth Rating | -80.7% |
| Fundamental | 17.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -68.5% |
| Analyst Rating | 4.89 of 5 |
CGEM Dividends
Currently no dividends paidCGEM Growth Ratios
| Growth Correlation 3m | -49.2% |
| Growth Correlation 12m | -90.8% |
| Growth Correlation 5y | -60.8% |
| CAGR 5y | -20.57% |
| CAGR/Max DD 3y | -0.26 |
| CAGR/Mean DD 3y | -0.68 |
| Sharpe Ratio 12m | -0.34 |
| Alpha | -80.56 |
| Beta | 0.708 |
| Volatility | 59.44% |
| Current Volume | 568.8k |
| Average Volume 20d | 557.4k |
| Stop Loss | 5.9 (-7.1%) |
| Signal | -1.56 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-206.8m TTM) > 0 and > 6% of Revenue (6% = -12.4m TTM) |
| FCFTA -0.28 (>2.0%) and ΔFCFTA -8.18pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.33 (>3.0%) and CFO -171.5m > Net Income -206.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 9.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (59.0m) change vs 12m ago 7.20% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover -34.37% (prev 0.0%; Δ -34.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -20.66
| (A) 0.48 = (Total Current Assets 275.9m - Total Current Liabilities 28.1m) / Total Assets 520.3m |
| (B) -0.94 = Retained Earnings (Balance) -486.8m / Total Assets 520.3m |
| (C) -0.39 = EBIT TTM -234.8m / Avg Total Assets 600.8m |
| (D) -17.25 = Book Value of Equity -486.2m / Total Liabilities 28.2m |
| Total Rating: -20.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 17.20
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -75.64% = -5.0 |
| 3. FCF Margin -70.38% = -7.50 |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda -0.01 = -2.50 |
| 6. ROIC - WACC -41.51% = -12.50 |
| 7. RoE -36.56% = -2.50 |
| 8. Revenue Trend data missing |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -12.12% = -0.30 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of CGEM shares?
Over the past week, the price has changed by -7.16%, over one month by -17.10%, over three months by -27.35% and over the past year by -62.49%.
Is Cullinan Oncology a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CGEM is around 4.51 USD . This means that CGEM is currently overvalued and has a potential downside of -28.98%.
Is CGEM a buy, sell or hold?
- Strong Buy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CGEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.2 | 312.9% |
| Analysts Target Price | 26.2 | 312.9% |
| ValueRay Target Price | 5 | -20.6% |
Last update: 2025-09-05 04:37
CGEM Fundamental Data Overview
CCE Cash And Equivalents = 265.5m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -206.8m + Cost of Revenue 306.0k = -206.5m USD
P/E Forward = 6.3012
P/S = 26.8794
P/B = 0.9267
Beta = -0.073
Revenue TTM = -206.5m USD
EBIT TTM = -234.8m USD
EBITDA TTM = -234.5m USD
Long Term Debt = 125.0k USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.39m USD (from shortTermDebt, last quarter)
Debt = 1.52m USD (Calculated: Short Term 1.39m + Long Term 125.0k)
Net Debt = -71.3m USD (from netDebt column, last quarter)
Enterprise Value = 192.1m USD (456.1m + Debt 1.52m - CCE 265.5m)
Interest Coverage Ratio = unknown (Ebit TTM -234.8m / Interest Expense TTM 0.0)
FCF Yield = -75.64% (FCF TTM -145.3m / Enterprise Value 192.1m)
FCF Margin = -70.38% (FCF TTM -145.3m / Revenue TTM -206.5m)
Net Margin = -100.1% (Net Income TTM -206.8m / Revenue TTM -206.5m)
Gross Margin = -100.1% ((Revenue TTM -206.5m - Cost of Revenue TTM 306.0k) / Revenue TTM)
Tobins Q-Ratio = -0.40 (set to none) (Enterprise Value 192.1m / Book Value Of Equity -486.2m)
Interest Expense / Debt = 303.8% (Interest Expense 4.62m / Debt 1.52m)
Taxrate = 21.0% (US default)
NOPAT = -234.8m (EBIT -234.8m, no tax applied on loss)
Current Ratio = 9.83 (Total Current Assets 275.9m / Total Current Liabilities 28.1m)
Debt / Equity = 0.00 (Debt 1.52m / last Quarter total Stockholder Equity 492.1m)
Debt / EBITDA = -0.01 (Net Debt -71.3m / EBITDA -234.5m)
Debt / FCF = -0.01 (Debt 1.52m / FCF TTM -145.3m)
Total Stockholder Equity = 565.5m (last 4 quarters mean)
RoA = -39.74% (Net Income -206.8m, Total Assets 520.3m )
RoE = -36.56% (Net Income TTM -206.8m / Total Stockholder Equity 565.5m)
RoCE = -41.50% (Ebit -234.8m / (Equity 565.5m + L.T.Debt 125.0k))
RoIC = -41.51% (NOPAT -234.8m / Invested Capital 565.5m)
WACC = unknown (E(456.1m)/V(457.6m) * Re(8.62%)) + (D(1.52m)/V(457.6m) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 66.67 | Cagr: 2.37%
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -145.3m)
EPS Correlation: -12.12 | EPS CAGR: 0.0% | SUE: -1.71 | # QB: False
Revenue Correlation: N/A | Revenue CAGR: 0.0%
Additional Sources for CGEM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle